Received Sep 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
potentially outside the stability conditions and given to a patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: potentially outside the stability conditions and given to a patient). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-SEP-2025 The Vaccine Administration Facility was the same as Primary Reporter The Medical Facility Supervisor reported that a Boostrix vaccine was transferred from the hospital to the office, without any devices to measure the temperature, in a cooler where the ice melted when it got to the office The reporter enquired what happens if the vaccine is administered to a patient.